0001209191-18-040127.txt : 20180629 0001209191-18-040127.hdr.sgml : 20180629 20180629195532 ACCESSION NUMBER: 0001209191-18-040127 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180627 FILED AS OF DATE: 20180629 DATE AS OF CHANGE: 20180629 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BRYANT DOUGLAS C CENTRAL INDEX KEY: 0001406652 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10961 FILM NUMBER: 18930582 MAIL ADDRESS: STREET 1: C/O QUIDEL CORPORATION STREET 2: 12544 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: QUIDEL CORP /DE/ CENTRAL INDEX KEY: 0000353569 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 942573850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12544 HIGH BLUFF DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8585521100 MAIL ADDRESS: STREET 1: 12544 HIGH BLUFF DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/ DATE OF NAME CHANGE: 19910210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-27 0 0000353569 QUIDEL CORP /DE/ QDEL 0001406652 BRYANT DOUGLAS C 12544 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130 1 1 0 0 President & CEO Common Stock 2018-06-27 4 M 0 12000 12.36 A 306313 D Common Stock 2018-06-27 4 S 0 12000 66.267 D 294313 D Common Stock 2018-06-28 4 M 0 12000 12.36 A 306313 D Common Stock 2018-06-28 4 S 0 12000 65.32 D 294313 D Common Stock 2018-06-29 4 M 0 12000 12.36 A 306313 D Common Stock 2018-06-29 4 S 0 12000 66.55 D 294313 D Non-Qualified Stock Option 12.36 2018-06-27 4 M 0 12000 0.00 D 2013-02-02 2019-02-02 Common Stock 12000 101212 D Non-Qualified Stock Option 12.36 2018-06-28 4 M 0 12000 0.00 D 2013-02-02 2019-02-02 Common Stock 12000 89212 D Non-Qualified Stock Option 12.36 2018-06-29 4 M 0 12000 0.00 D 2013-02-02 2019-02-02 Common Stock 12000 77212 D The weighted average sale price for these transactions was $66.267 per share, with a range of $65.19 to $67.71. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. The weighted average sale price for these transactions was $65.32 per share, with a range of $64.47 to $66.48. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. The weighted average sale price for these transactions was $66.55 per share, with a range of $65.91 to $66.83. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. All transactions reported herein were effected pursuant to a pre-established 10b5-1 trading plan. Robert J. Bujarski, attorney-in-fact for Douglas C. Bryant 2018-06-29